All In Biotech

Drug Trial Radar · NCT04692688

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

103

Actual

Start

Apr 8, 2021

Primary completion

Jan 25, 2023

Study completion Jan 25, 2023

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
First posted
Jan 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).

Conditions

  • Diabetic Retinopathy
  • Diabetic Macular Edema
  • NPDR - Non Proliferative Diabetic Retinopathy
  • PDR - Proliferative Diabetic Retinopathy

Interventions

  • APX3330Drug

    APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.

  • PlaceboDrug

    Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Subjects With ≥ 2-step Improvement in Diabetic Retinopathy Severity Score (DRSS)Time frame: 24 Weeks

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site 9

    Phoenix, Arizona

  • Clinical Site 8

    Bakersfield, California

  • Clinical Site 5

    Beverly Hills, California

  • Clinical Site 11

    Palm Desert, California

  • Clinical Site 2

    Sacramento, California

  • Clinical Site 24

    Walnut Creek, California

  • Clinical Site 19

    Miami, Florida

  • Clinical Site 7

    Winter Haven, Florida

  • Clinical Site 6

    Carmel, Indiana

  • Clinical Site 14

    Hagerstown, Maryland

  • Clinical Site 22

    Springfield, Massachusetts

  • Clinical Site 17

    Grand Blanc, Michigan

  • Clinical Site 12

    Albuquerque, New Mexico

  • Clinical Site 15

    Shirley, New York

  • Clinical Site 20

    Charlotte, North Carolina

  • Clinical Site 1

    Rapid City, South Dakota

  • Clinical Site 18

    Austin, Texas

  • Clinical Site 16

    Bellaire, Texas

  • Clinical Site 10

    Fort Worth, Texas

  • Clinical Site 4

    McAllen, Texas

  • Clinical Site 3

    San Antonio, Texas

  • Clinical Site 23

    San Antonio, Texas

  • Clinical Site 13

    Southlake, Texas

  • Clinical Site 21

    Ogden, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.